Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 21, 2025Neuro-Oncology

Co-activation of super-enhancer complex SOX2 and HDAC1 confers temozolomide resistance by promoting PDGFB transcription in glioblastoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HXHan XieTJTongjie JiCZChunyu Zhang

Discussion

Loading...

Member takes

Overview

Functional analysis reveals that super-enhancer complex SOX2 and HDAC1 promote PDGFB transcription, highlighting implications for treatment strategies.

Key Points

  • Inhibition of SOX2 enhances the effectiveness of temozolomide in glioblastoma treatment.
  • SOX2 upregulation in TMZ-resistant patient-derived cells correlates with poor prognosis in recurrent glioblastoma patients.
  • The mechanism involves the SOX2 and HDAC1 complex promoting PDGFB transcription, which activates signaling pathways linked to drug resistance.
  • Targeting the super-enhancer complex may present a new therapeutic strategy to improve clinical outcomes in glioblastoma patients.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/68d43afa713b0b5dfea7acefhttps://doi.org/10.1093/neuonc/noaf219
View Full Paper
Ask AI
Bookmark
Share